Polygenic methylation patterns are linked to osimertinib resistance in non-small cell lung cancer
Methylation Patterns Linked to Drug Resistance in Lung Cancer
This systematic review examines the role of polygenic DNA and RNA methylation in osimertinib resistance for patients with non-small cell lun…
New research identifies how changes in DNA and RNA methylation may contribute to drug resistance in patients with non-small cell lung cancer…
Osimertinib plus chemotherapy improves progression-free survival by 18.4 months in TP53 and EGFR-mutated NSCLC
Adding chemotherapy to osimertinib extends survival for specific lung cancer
This Phase 3 randomized clinical trial of 294 treatment-naive, stage IV or recurrent nonsquamous NSCLC patients with concurrent TP53 and EGF…
A new combination of osimertinib and chemotherapy significantly extends the time patients with specific lung cancer mutations live without d…
Osimertinib treatment for EGFR-mutated NSCLC results in hypertension as the most common CVAE
Osimertinib treatment for lung cancer shows specific heart risks
This meta-analysis of 10,316 patients with EGFR-mutated non-small cell lung cancer evaluated cardiovascular adverse events (CVAEs) associate…
New data identifies hypertension as the most common heart-related side effect for patients taking osimertinib for certain types of lung canc…
Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
Osimertinib may help some lung cancer patients after resistance develops
This narrative review examines the use of osimertinib and other EGFR-TKIs in non-small cell lung cancer patients harboring EGFR mutations af…
A review suggests osimertinib could be an option for non-small cell lung cancer patients with EGFR mutations who develop resistance to earli…
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases
Untreated Brain Metastases Respond Well to Osimertinib
This single-arm phase II trial evaluated first-line osimertinib in 100 patients with EGFR-mutated non-small cell lung cancer, including thos…
Osimertinib, a lung cancer drug, effectively treats untreated brain metastases, with an 81.8% response rate for measurable brain spots in a …
Amivantamab-lazertinib shows OS benefit over osimertinib in Asian EGFR-mutant NSCLC subset
Combination therapy shows longer survival than standard drug in Asian lung cancer patients
In a subset analysis of an RCT of 629 Asian patients with untreated EGFR-mutant advanced NSCLC, amivantamab-lazertinib prolonged overall sur…
Asian lung cancer patients on a new two-drug combination therapy lived longer than those taking the standard single drug, with a 26% lower r…